Skip to main content

Premier of South Australia Steven Marshall Briefed on $50 billion Clinical Trial Sector During Visit to Adelaide-based Avance Clinical

By June 1, 2020July 13th, 2021Company News

The leading Australian CRO for biotechs, Avance Clinical, hosted a visit with the Premier of South Australia the Hon. Steven Marshall MP to discuss the fast-growing clinical trials sector, currently worth $50 billion and increasing to $71.7 billion by 2024 according to Frost & Sullivan.

Avance Clinical manages biotech clinical trials in Australia, from its headquarters in South Australia, working with hundreds of clinics and research teams around the country to assess new drugs for regulatory approval that could make a real difference to people’s lives.

The Premier toured the facility in Thebarton and took a briefing on the sector from Avance CEO Yvonne Lungershausen and her team.

Avance Clinical CEO Yvonne Lungershausen said:

“Most of Avance Clinical’s biotech clients are from the USA while numbers from the EU and Asia are on the increase, particularly from China and South Korea.

Australia is a well-established location for international clinical trials and our management of the COVID-19 crisis has made it an even more attractive trials destination.

South Australia has managed the COVID-19 pandemic extremely well, allowing Avance Clinical to continue operations throughout the crisis. However, in other countries clinical trials have been suspended or closed, putting extreme pressure on the biotech sector.”

There are currently 764 clinical studies underway or planned in South Australia alone and a total of 2,225 in Australia.” (ClinicalTrials.Gov)

Avance Clinical is a medium-sized full-service CRO known for its nimble and collaborative approach, with more than 20-years of experience in managing early phase trials.

In addition to the impressive COVID-19 management, a key factor in sponsor demand is the speed, and attractive cost of running trials in Australia including:

  • The Australian Government financial rebate of more than 40% on clinical trial spend
  • No IND required for clinical trials and streamlined regulatory processes
  • Advanced medical, research and scientific community, leading investigators and KOLs, and modern medical facilities

Watch video – how we work during the COVID-19 pandemic here.

Australia’s reputation for FDA compliant scientific and research excellence, its advanced healthcare, and the opportunity to access patients in a less clinical trial competitive environment further reinforces its advantage as a destination for clinical trials.

Leave a Reply